JP2022505381A5 - - Google Patents
Info
- Publication number
- JP2022505381A5 JP2022505381A5 JP2021521383A JP2021521383A JP2022505381A5 JP 2022505381 A5 JP2022505381 A5 JP 2022505381A5 JP 2021521383 A JP2021521383 A JP 2021521383A JP 2021521383 A JP2021521383 A JP 2021521383A JP 2022505381 A5 JP2022505381 A5 JP 2022505381A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid construct
- bidirectional nucleic
- bidirectional
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747522P | 2018-10-18 | 2018-10-18 | |
| US62/747,522 | 2018-10-18 | ||
| PCT/US2019/057092 WO2020082047A1 (en) | 2018-10-18 | 2019-10-18 | Compositions and methods for treating alpha-1 antitrypsin deficiencey |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022505381A JP2022505381A (ja) | 2022-01-14 |
| JP2022505381A5 true JP2022505381A5 (cg-RX-API-DMAC7.html) | 2022-10-27 |
Family
ID=68468858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521383A Pending JP2022505381A (ja) | 2018-10-18 | 2019-10-18 | アルファ1アンチトリプシン欠乏症を治療するための組成物及び方法 |
Country Status (16)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7383478B2 (ja) * | 2016-12-22 | 2023-11-20 | インテリア セラピューティクス,インコーポレイテッド | アルファ1アンチトリプシン欠乏症を治療するための組成物および方法 |
| IL326835A (en) | 2018-10-16 | 2026-04-01 | Blueallele Llc | Methods for targeted insertion of dna genes |
| JP7578590B2 (ja) | 2018-10-18 | 2024-11-06 | インテリア セラピューティクス,インコーポレーテッド | 第ix因子を発現するための組成物及び方法 |
| CN113454105A (zh) | 2019-02-08 | 2021-09-28 | 克里斯托生物技术股份有限公司 | 用于递送cftr多肽的组合物和方法 |
| CN113939595A (zh) | 2019-06-07 | 2022-01-14 | 瑞泽恩制药公司 | 包括人源化白蛋白基因座的非人动物 |
| US12521451B2 (en) | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
| CA3198727A1 (en) * | 2020-10-20 | 2022-04-28 | St Pharm Co., Ltd. | Oligonucleotide for 5'-capped rna synthesis |
| US20220160847A1 (en) * | 2020-11-20 | 2022-05-26 | Mark Egly | Method of preventing and/or treating a plurality of diseases |
| KR20240100492A (ko) * | 2021-10-15 | 2024-07-01 | 인텔리아 테라퓨틱스, 인크. | 알파-1 항트립신 결핍을 치료하기 위한 조성물 및 방법 |
| MX2024004812A (es) * | 2021-10-19 | 2024-07-15 | Prec Biosciences Inc | Métodos de edición génica para el tratamiento de la deficiencia de alfa-1 antitripsina (aat). |
| WO2024254519A2 (en) * | 2023-06-08 | 2024-12-12 | Mammoth Biosciences, Inc. | Compositions and methods for the modification of human genes expressed by liver cells |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
| CA2186118C (en) | 1994-03-23 | 2010-10-19 | Richard W. Hanson | Compacted nucleic acids and their delivery to cells |
| EP0760008A1 (en) | 1994-05-19 | 1997-03-05 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
| CA2720903C (en) | 2008-04-14 | 2019-01-15 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| JP5908725B2 (ja) | 2008-08-22 | 2016-04-26 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 標的一本鎖開裂および標的組込みのための方法、並びに組成物 |
| US9255259B2 (en) | 2010-02-09 | 2016-02-09 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| EP4397759A3 (en) | 2012-10-23 | 2024-10-09 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| EP2997146A4 (en) * | 2013-05-15 | 2017-04-26 | Sangamo BioSciences, Inc. | Methods and compositions for treatment of a genetic condition |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| WO2015200555A2 (en) | 2014-06-25 | 2015-12-30 | Caribou Biosciences, Inc. | Rna modification to engineer cas9 activity |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| CN113337533A (zh) | 2014-12-23 | 2021-09-03 | 先正达参股股份有限公司 | 用于鉴定和富集包含位点特异性基因组修饰的细胞的方法和组合物 |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| US11279928B2 (en) | 2015-06-29 | 2022-03-22 | Massachusetts Institute Of Technology | Compositions comprising nucleic acids and methods of using the same |
| WO2017093804A2 (en) * | 2015-12-01 | 2017-06-08 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
| WO2017136794A1 (en) | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| EP3433364A1 (en) * | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency |
| ES3030658T3 (en) | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| EP3551757A1 (en) | 2016-12-08 | 2019-10-16 | Intellia Therapeutics, Inc. | Modified guide rnas |
| JP7383478B2 (ja) | 2016-12-22 | 2023-11-20 | インテリア セラピューティクス,インコーポレイテッド | アルファ1アンチトリプシン欠乏症を治療するための組成物および方法 |
| IL311278B2 (en) | 2017-09-29 | 2026-05-01 | Intellia Therapeutics Inc | Polynucleotides, compositions, and methods for genome editing |
| IL326835A (en) | 2018-10-16 | 2026-04-01 | Blueallele Llc | Methods for targeted insertion of dna genes |
-
2019
- 2019-10-18 MX MX2021004276A patent/MX2021004276A/es unknown
- 2019-10-18 AU AU2019361204A patent/AU2019361204A1/en not_active Abandoned
- 2019-10-18 CA CA3116739A patent/CA3116739A1/en active Pending
- 2019-10-18 EP EP19798480.0A patent/EP3867378A1/en active Pending
- 2019-10-18 CN CN201980082770.6A patent/CN113195721A/zh active Pending
- 2019-10-18 BR BR112021007289-6A patent/BR112021007289A2/pt unknown
- 2019-10-18 TW TW108137783A patent/TW202027797A/zh unknown
- 2019-10-18 SG SG11202103735TA patent/SG11202103735TA/en unknown
- 2019-10-18 EA EA202191067A patent/EA202191067A1/ru unknown
- 2019-10-18 WO PCT/US2019/057092 patent/WO2020082047A1/en not_active Ceased
- 2019-10-18 KR KR1020217014893A patent/KR20210102209A/ko not_active Ceased
- 2019-10-18 JP JP2021521383A patent/JP2022505381A/ja active Pending
- 2019-10-18 US US16/657,967 patent/US20200270618A1/en active Pending
-
2021
- 2021-04-11 IL IL282237A patent/IL282237A/en unknown
- 2021-04-15 PH PH12021550842A patent/PH12021550842A1/en unknown
- 2021-05-18 CO CONC2021/0006367A patent/CO2021006367A2/es unknown
-
2025
- 2025-09-23 US US19/337,426 patent/US20260125690A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7832262B2 (ja) | 肝特異的ウイルスプロモーター及びその使用方法 | |
| JP2023523237A (ja) | snRNA構成要素を使用する組成物及び方法 | |
| EP2940131B1 (en) | Aav variant | |
| JP6495273B2 (ja) | 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法 | |
| JP2022513456A5 (cg-RX-API-DMAC7.html) | ||
| JP2022534809A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512726A5 (cg-RX-API-DMAC7.html) | ||
| CN114450031A (zh) | 靶向rna的敲低和替代组合物及使用方法 | |
| JP6824169B2 (ja) | 改変g6pcをコードするアデノ随伴ウイルスベクターおよびその使用 | |
| JP2016517278A (ja) | スタッファー/フィラーポリヌクレオチド配列を含むベクターおよびその使用方法 | |
| JP2022553573A5 (cg-RX-API-DMAC7.html) | ||
| CN119137273A (zh) | 包括工程化核内小RNA(snRNA)的组合物和方法 | |
| WO2019152816A1 (en) | Campaign-ready series of recombinant adeno-associated virus (raav) complementing plasmids | |
| WO2020142714A1 (en) | Aav expression cassette and aav vectors comprising the same | |
| US20240398990A1 (en) | Liver-specific expression cassettes, vectors and uses thereof for expressing therapeutic proteins | |
| CN119403823A (zh) | 具有增强的肌肉转导效率的肽修饰的aav衣壳 | |
| JP2024546196A (ja) | USH2A pre-mRNAを標的とするsnRNA、及びその使用 | |
| CN120129747A (zh) | snRNA核酸分子及其应用 | |
| EP4100523A2 (en) | Compositions and methods for circular rna expression | |
| TWI903434B (zh) | 具有改良負載基因表現率及降低基因毒性之腺相關病毒之經修飾複合體平台 | |
| US11993783B1 (en) | Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof | |
| CN112041437A (zh) | 用于恢复f8基因功能的腺相关病毒组合物和其使用方法 | |
| JP2025500685A (ja) | ヌクレオチド及びその使用 | |
| CN105358690B (zh) | 启动子组合物 | |
| JP2022523320A5 (cg-RX-API-DMAC7.html) |